{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T12:26:13Z","timestamp":1794313573059,"version":"4.9.0"},"reference-count":24,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2021,10,18]],"date-time":"2021-10-18T00:00:00Z","timestamp":1634515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,7,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background and Aims<\/jats:title>\n                  <jats:p>Patients with ulcerative colitis [UC] are at increased risk of colorectal cancer. Anti-tumour necrosis factor agents [anti-TNF] aim to reduce chronic colonic inflammation and may lower the risk of colorectal cancer [CRC], but the impact of anti-TNF exposure has not yet been assessed in population-based cohort studies. The aim of this nationwide study was to assess the risk of CRC in patients with UC exposed to anti-TNF.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Based on the French health insurance database, patients aged 18 years or older with a diagnosis of UC, previously exposed to or initiating immunosuppressive treatment, were followed from January 1, 2009, until December 31, 2018. The risk of CRC associated with anti-TNF exposure was assessed using marginal structural Cox proportional hazard models adjusting for baseline and time-varying comorbidities including primary sclerosing cholangitis, UC disease activity, colonoscopic surveillance, and other medications.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Among 32 403 patients with UC, 15 542 [48.0%] were exposed to anti-TNF. During a median follow-up of 6.1 years [198 249 person-years], 246 incident CRC occurred (incidence rate per 1000 person-years, 1.24; 95% confidence intrval [CI], 1.10-1.41). Whereas the risk of CRC associated with anti-TNF exposure was not decreased in the overall group of patients with UC (hazard ratio [HR], 0.85; 95% CI, 0.58-1.26), anti-TNF exposure was associated with a decreased risk of CRC in patients with long-standing colitis [disease duration \u226510 years] [HR, 0.41; 95% CI, 0.20-0.86].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>In a nationwide cohort of patients with UC, anti-TNF exposure was associated with a decreased risk of CRC in patients with long-standing colitis.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/ecco-jcc\/jjab184","type":"journal-article","created":{"date-parts":[[2021,10,16]],"date-time":"2021-10-16T00:49:59Z","timestamp":1634345399000},"page":"893-899","source":"Crossref","is-referenced-by-count":26,"title":["Impact of Anti-tumour Necrosis Factor Agents on the Risk of Colorectal Cancer in Patients with Ulcerative Colitis: Nationwide French Cohort Study"],"prefix":"10.1093","volume":"16","author":[{"given":"Maeva","family":"Charkaoui","sequence":"first","affiliation":[{"name":"AP-HP Sorbonne Universit\u00e9, H\u00f4pital Saint-Antoine, Department of Gastroenterology , Paris , France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Hajage","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"},{"name":"AP-HP Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florence","family":"Tubach","sequence":"additional","affiliation":[{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"},{"name":"AP-HP Sorbonne Universit\u00e9, H\u00f4pital Piti\u00e9 Salp\u00eatri\u00e8re, D\u00e9partement de Sant\u00e9 Publique, Centre de Pharmaco\u00e9pid\u00e9miologie , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Beaugerie","sequence":"additional","affiliation":[{"name":"AP-HP Sorbonne Universit\u00e9, H\u00f4pital Saint-Antoine, Department of Gastroenterology , Paris , France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julien","family":"Kirchgesner","sequence":"additional","affiliation":[{"name":"AP-HP Sorbonne Universit\u00e9, H\u00f4pital Saint-Antoine, Department of Gastroenterology , Paris , France"},{"name":"Sorbonne Universit\u00e9, INSERM, Institut Pierre Louis d\u2019Epid\u00e9miologie et de Sant\u00e9 Publique , Paris , France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,10,18]]},"reference":[{"key":"2022071420382303400_CIT0001","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1053\/j.gastro.2013.03.044","article-title":"Risk of colorectal high-grade dysplasia and cancer in a prospective observational cohort of patients with inflammatory bowel disease","volume":"145","author":"Beaugerie","year":"2013","journal-title":"Gastroenterology"},{"key":"2022071420382303400_CIT0002","article-title":"Prognostic factors for advanced colorectal neoplasia in inflammatory bowel disease: systematic review and meta-analysis","author":"Wijnands","year":"2020","journal-title":"Gastroenterology"},{"key":"2022071420382303400_CIT0003","doi-asserted-by":"crossref","first-page":"G7","DOI":"10.1152\/ajpgi.00079.2004","article-title":"Inflammation and cancer IV. Colorectal cancer in inflammatory bowel disease: the role of inflammation","volume":"287","author":"Itzkowitz","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"2022071420382303400_CIT0004","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1056\/NEJMra1403718","article-title":"Cancers complicating inflammatory bowel disease","volume":"372","author":"Beaugerie","year":"2015","journal-title":"N Engl J Med"},{"key":"2022071420382303400_CIT0005","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1016\/j.cgh.2012.01.010","article-title":"Risk of colorectal cancer in patients with ulcerative colitis: a meta-analysis of population-based cohort studies","volume":"10","author":"Jess","year":"2012","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382303400_CIT0006","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.cgh.2018.07.013","article-title":"Balancing benefit vs risk of immunosuppressive therapy for individual patients with inflammatory bowel diseases","volume":"17","author":"Beaugerie","year":"2019","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382303400_CIT0007","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.cgh.2019.05.002","article-title":"Nancy Index scores of chronic inflammatory bowel disease activity associate with development of colorectal neoplasia","volume":"18","author":"Kirchgesner","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382303400_CIT0008","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1136\/gut.2011.237412","article-title":"Thiopurines prevent advanced colorectal neoplasia in patients with inflammatory bowel disease","volume":"61","author":"van Schaik","year":"2012","journal-title":"Gut"},{"key":"2022071420382303400_CIT0009","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1093\/ecco-jcc\/jjv145","article-title":"Thiopurine therapy reduces the incidence of colorectal neoplasia in patients with ulcerative colitis. Data from the ENEIDA Registry","volume":"9","author":"Gordillo","year":"2015","journal-title":"J Crohns Colitis"},{"key":"2022071420382303400_CIT0010","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1016\/j.cgh.2016.04.039","article-title":"Biologic therapies and risk of infection and malignancy in patients with inflammatory bowel disease: a systematic review and network meta-analysis","volume":"14","author":"Bonovas","year":"2016","journal-title":"Clin Gastroenterol Hepatol"},{"key":"2022071420382303400_CIT0011","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1093\/ecco-jcc\/jjy006","article-title":"Reduced risk of inflammatory bowel disease-associated colorectal neoplasia with use of thiopurines: a systematic review and meta-analysis","volume":"12","author":"Zhu","year":"2018","journal-title":"J Crohns Colitis"},{"key":"2022071420382303400_CIT0012","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1001\/jama.2014.5613","article-title":"Association between tumor necrosis factor-\u03b1 antagonists and risk of cancer in patients with inflammatory bowel disease","volume":"311","author":"Nyboe Andersen","year":"2014","journal-title":"JAMA"},{"key":"2022071420382303400_CIT0013","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1111\/apt.13835","article-title":"Therapeutic management of inflammatory bowel disease in real-life practice in the current era of anti-TNF agents: analysis of the French administrative health databases 2009\u20132014","volume":"45","author":"Kirchgesner","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382303400_CIT0014","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1002\/pds.4233","article-title":"The national healthcare system claims databases in France, SNIIRAM and EGB: Powerful tools for pharmacoepidemiology","volume":"26","author":"Bezin","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022071420382303400_CIT0015","doi-asserted-by":"crossref","first-page":"1679","DOI":"10.1001\/jama.2017.16071","article-title":"Association between use of thiopurines or tumor necrosis factor antagonists alone or in combination and risk of lymphoma in patients with inflammatory bowel disease","volume":"318","author":"Lemaitre","year":"2017","journal-title":"JAMA"},{"key":"2022071420382303400_CIT0016","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1136\/gutjnl-2019-318932","article-title":"Risk of acute arterial events associated with treatment of inflammatory bowel diseases: nationwide French cohort study","volume":"69","author":"Kirchgesner","year":"2020","journal-title":"Gut"},{"key":"2022071420382303400_CIT0017","doi-asserted-by":"crossref","first-page":"935","DOI":"10.1002\/pds.4225","article-title":"Evaluation of algorithms to identify incident cancer cases by using French health administrative databases","volume":"26","author":"Ajrouche","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"2022071420382303400_CIT0018","doi-asserted-by":"crossref","first-page":"2348","DOI":"10.1016\/j.jacc.2017.02.065","article-title":"Cardiovascular risk and known coronary artery disease are associated with colorectal adenoma and advanced neoplasia","volume":"69","author":"Niederseer","year":"2017","journal-title":"J Am Coll Cardiol"},{"key":"2022071420382303400_CIT0019","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0140-6736(19)32545-0","article-title":"Colorectal cancer in ulcerative colitis: a Scandinavian population-based cohort study","volume":"395","author":"Ol\u00e9n","year":"2020","journal-title":"Lancet"},{"key":"2022071420382303400_CIT0020","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/00001648-200009000-00012","article-title":"Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men","volume":"11","author":"Hern\u00e1n","year":"2000","journal-title":"Epidemiology"},{"key":"2022071420382303400_CIT0021","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1093\/aje\/kwn164","article-title":"Constructing inverse probability weights for marginal structural models","volume":"168","author":"Cole","year":"2008","journal-title":"Am J Epidemiol"},{"key":"2022071420382303400_CIT0022","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/ajg.2013.249","article-title":"Cancer risk in inflammatory bowel disease according to patient phenotype and treatment: a Danish population-based cohort study","volume":"108","author":"Jess","year":"2013","journal-title":"Am J Gastroenterol"},{"key":"2022071420382303400_CIT0023","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1111\/apt.14030","article-title":"Systematic review with meta-analysis: comparative efficacy of biologics for induction and maintenance of mucosal healing in Crohn\u2019s disease and ulcerative colitis controlled trials","volume":"45","author":"Cholapranee","year":"2017","journal-title":"Aliment Pharmacol Ther"},{"key":"2022071420382303400_CIT0024","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1097\/01.MIB.0000436277.13917.c4","article-title":"Initial disease course and treatment in an inflammatory bowel disease inception cohort in Europe: the ECCO-EpiCom cohort","volume":"20","author":"Burisch","year":"2014","journal-title":"Inflamm Bowel Dis"}],"container-title":["Journal of Crohn's and Colitis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/advance-article-pdf\/doi\/10.1093\/ecco-jcc\/jjab184\/41163040\/jjab184.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/893\/44890498\/jjab184.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article-pdf\/16\/6\/893\/44890498\/jjab184.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,7,14]],"date-time":"2022-07-14T20:39:04Z","timestamp":1657831144000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ecco-jcc\/article\/16\/6\/893\/6399096"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,10,18]]},"references-count":24,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2021,10,18]]},"published-print":{"date-parts":[[2022,7,14]]}},"URL":"https:\/\/doi.org\/10.1093\/ecco-jcc\/jjab184","relation":{},"ISSN":["1873-9946","1876-4479"],"issn-type":[{"value":"1873-9946","type":"print"},{"value":"1876-4479","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,6,1]]},"published":{"date-parts":[[2021,10,18]]}}}